File: '\\swfile\EmailIn\20250106 132724 Attachment 2025_01_06 ENBI NR closing of NBPP financing.docx'

Entheon Biomedical Announces Closing of Private Placement Financing

VANCOUVER, BC, January 6, 2025 - Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") is pleased to announce that, further to its news releases dated December 2, 2024 and December 24, 2024, it has closed a non-brokered private placement for total gross proceeds of CDN$500,000 (the "Placement").

The Company has allotted and issued 5,000,000 units (the "Units") at a price of CDN$0.10 per Unit. Each unit consists of one common share of the Company and one transferable share purchase warrant, with each warrant entitling the holder to acquire one additional common share at an exercise price of CDN$0.15 for a period of 24 months from the date of issuance.

The Company will use the proceeds from the Placement towards general working capital purposes. All securities issued under the Placement are subject to a hold period of four months and one day expiring on May 4, 2025.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,

Timothy Ko, CEO, President and Director

For more information, please contact the Company at:

Entheon Biomedical Corp.

Timothy Ko, CEO

timothy@entheonbiomedical.com

https://entheonbiomedical.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws. Forward-Looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include the future performance of the Company. Forward-Looking statements are based on the opinions and estimates at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedarplus.ca.